Compare Boston Scientific Corporation (BSX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $239.75 (market cap $44.01B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | TTWO | |
|---|---|---|
Market Cap | $66.37B | $44.01B |
Sector | Health | Media |
52-Week High | $108.14 | $262.29 |
52-Week Low | $42.63 | $189.69 |
Enterprise Value | $75.94B | $44.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Take-Two Interactive (TTWO) trades at $244.10, up 0.37% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The stock has consistently beaten earnings expectations in recent quarters, though it reported a net loss of -$4.48 billion in FY2025. Sentiment is highly positive due to strong pre-orders for Grand Theft Auto VI, priced at $79.99 with a November 2026 launch, driving analyst optimism.
The outlook is driven by GTA VI's monetization potential, with a consensus price target of $302.50 implying 24% upside. Risks include high debt levels, negative profitability, and execution challenges. Institutional confidence remains strong with 79% buy ratings, but investors should monitor cash flow trends and competitive pressures in the gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
